<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844763</url>
  </required_header>
  <id_info>
    <org_study_id>2017-000353-39</org_study_id>
    <nct_id>NCT03844763</nct_id>
  </id_info>
  <brief_title>Targeting the Tumor Microenvironment in R/M SCCHN</brief_title>
  <acronym>CONFRONT</acronym>
  <official_title>The CONFRONT Phase I - II Trial: ACtivatiON oF Immune RespONse in paTients With R-M Head and Neck Cancer. Multimodality Immunotherapy With Avelumab, Short Course Radiotherapy and Cyclophosphamide in Head and Neck Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico del Nord-Ovest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Oncologico del Nord-Ovest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I - II trial of the combination of cyclophosphamide, RT, and Avelumab in&#xD;
      relapsed/metastatic HNSCC (R/M-HNC). Patients pretreated with at least one line therapy&#xD;
      containing platinum, fluorouracil, and Cetuximab. Treatment consists of metronomic&#xD;
      cyclophosphamide 50 mg daily without drug free break, avelumab 10 mg/kg d1 and 15 q 29, and&#xD;
      radiotherapy in one or three daily fractions up to 8 Gy maximum dose, starting at day 8. The&#xD;
      aim of the study is to reverse tumor immune-escape by:&#xD;
&#xD;
        1. Provide a self-vaccination with radiotherapy&#xD;
&#xD;
        2. Inhibit the immunosuppressive CD4+ CD25+ FoxP3+ Treg cells with metronomic&#xD;
           cyclophosphamide&#xD;
&#xD;
        3. Reactivate the effector T cell by the inhibition of PD-1 - PD-L1 axis with avelumab.&#xD;
&#xD;
      Due to the supposed biological effects of the present trial, an ancillary translational study&#xD;
      is needed and will be extended to all the patients' population enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rational of the trial&#xD;
&#xD;
      A phase I - II trial in RM-HNC based on pharmacologic and physic interventions related to&#xD;
      each other facing immunology as a system rather than a single pathway, theoretically able to&#xD;
      restore immune competence toward the tumor. The immune suppressive mechanisms that could be&#xD;
      affected by this study and how the experimental approach could inhibit them, are listed&#xD;
      below:&#xD;
&#xD;
        -  PD-1 - PD-L1 axis is widespread among immune cell family including CTL, Treg, NK, NKT,&#xD;
           APC and others showing, for example, opposite effect in CD8+ CTL (inhibitory signal) or&#xD;
           in CD4+ CD25+ Foxp3+ (activating signal).&#xD;
&#xD;
        -  Depletion of Treg results in tumor regression, in experimental models. The effect seems&#xD;
           to be dependent on the extent of Treg suppression.&#xD;
&#xD;
        -  Avelumab is a fully human anti-PD-L1 IgG1 monoclonal antibody. It enables the activation&#xD;
           of T-cells and the adaptive immune system by inhibiting PD-1 - PD-L1 axis, induces&#xD;
           antibody-dependent cell-mediated cytotoxicity (ADCC) and engages the innate immune&#xD;
           system.&#xD;
&#xD;
        -  Low dose cyclophosphamide (metronomic cyclophosphamide), selectively reduce Treg&#xD;
           population both in experimental models and in humans, but it does not affect effector T&#xD;
           cells&#xD;
&#xD;
        -  PD-1 - PD-L1 axis enhances and sustains Foxp3 expression and the suppressive function of&#xD;
           inducible Tregs (iTrge)7. The blockade of the PD1 - PDL1 axis by Avelumab may have an&#xD;
           opposite effect.&#xD;
&#xD;
        -  The contemporary use of two, independent, mechanisms of Treg control (Avelumab&#xD;
           inhibiting Treg clonal expansion and functions, and cyclophosphamide reducing Treg&#xD;
           population) may result in a profound inhibition of Treg population.&#xD;
&#xD;
        -  If the suppressive mechanisms of the immune system are weakened, the release of high&#xD;
           quantity of tumor specific antigens or stress related antigens (epcam, HSPs, HMBG-1,&#xD;
           Calreticulin, ATP), obtained by the induction of immunogenic cell death may induce a&#xD;
           sort of &quot;self vaccination&quot; resulting into an effective immune response.&#xD;
&#xD;
        -  Radiation may induce immunogenic cell death even in heavily pretreated patients in whom&#xD;
           the use of cytotoxic chemotherapy may not, due to the previous exposure to drugs and the&#xD;
           development of resistance mechanisms. More precisely, this effect is considered the&#xD;
           basis of the Abscopal effect, i.e. the regression of tumor deposits outside the&#xD;
           irradiated field. This effect is more frequently observed with low-dose, non ablative,&#xD;
           hypofractionated radiation therapy (described at point 2.3.2) and represent a proof of&#xD;
           concept that in particular situations, radiotherapy act as an inducer of &quot;self&#xD;
           vaccination&quot;.&#xD;
&#xD;
        -  IgG1 mAbs, such as Avelumab, triggers ADCC; PD-L1 is widely express in many tumors and&#xD;
           so ADCC may represent an additional mechanism of tumor control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>4 months</time_frame>
    <description>Assessment of the safety profile of the association of avelumab and metronomic cyclophosphamide will be graded using the common toxicity criteria and adverse events (NCI CTC-AE v 4.0).Grade refers to the severity of the AE. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. Each adverse event will be reported as the maximum level observed in each patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2-4 months</time_frame>
    <description>Objective response is defined as complete response or partial response as defined as per RECIST evaluation criteria v1.1 (RECIST 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of the combination</measure>
    <time_frame>1 month</time_frame>
    <description>Assessment of the safety profile of the association of avelumab and metronomic cyclophosphamide will be graded using the common toxicity criteria and adverse events (NCI CTC-AE v 4.0).Grade refers to the severity of the AE. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. Each adverse event will be reported as the maximum level observed in each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>54 months</time_frame>
    <description>Progression free survival is defined as the time from study treatment initiation to the first occurrence of disease progression or death of any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>2 months</time_frame>
    <description>Quality of Life will be assessed using the EORTC QLQ -30. Grade 1 to 4. Grade 1: not at all, Grade 4: Very much</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>H&amp;N specific Quality of Life (QoL)</measure>
    <time_frame>2 months</time_frame>
    <description>Quality of Life will be assessed using the EORTC QLQ - H&amp;N35. Grade 1 to 4. Grade 1: not at all, Grade 4: Very much</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>54 months</time_frame>
    <description>Overall survival is defined as the time from treatment initiation to death for any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I - II trial of CTX, RT, Avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTX: 50 mg Daily untill PD or major toxicity; Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity; RT: 8 Gy single shot day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity</description>
    <arm_group_label>Phase I - II trial of CTX, RT, Avelumab</arm_group_label>
    <other_name>anti PD-L1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX</intervention_name>
    <description>CTX: 50 mg Daily untill PD or major toxicity</description>
    <arm_group_label>Phase I - II trial of CTX, RT, Avelumab</arm_group_label>
    <other_name>cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>RT</intervention_name>
    <description>RT: 8 Gy single shot day 8</description>
    <arm_group_label>Phase I - II trial of CTX, RT, Avelumab</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be willing and able to provide written informed consent for the trial. The subject may&#xD;
             also provide consent for the translational study.&#xD;
&#xD;
          2. Be 18 years of age on day of signing informed consent.&#xD;
&#xD;
          3. ECOG Performance Status 0-2.&#xD;
&#xD;
          4. Have histologically or cytologically-confirmed recurrent or metastatic (disseminated)&#xD;
             head and neck squamous cell carcinoma&#xD;
&#xD;
          5. Have a disease progression after treatment with at least one line of therapy including&#xD;
             at least Cisplatin, Fluorouracil and Cetuximab for recurrent (disease not amenable to&#xD;
             curative treatment)/metastatic disease.&#xD;
&#xD;
          6. Measurable disease by RECIST criteria.&#xD;
&#xD;
          7. At least one metastatic site suitable for irradiation&#xD;
&#xD;
          8. Life expectancy &gt; 3 months.&#xD;
&#xD;
          9. Adequate bone marrow function: neutrophils 1.5 x 109/L, platelets 100 x 109/L,&#xD;
             hemoglobin 9 g/dL.&#xD;
&#xD;
         10. Adequate liver function: AST and ALT levels 2.5 × ULN; bilirubin 1.5 x ULN.&#xD;
&#xD;
         11. Adequate renal function: creatinine clearance 30 mL/min (Cockroft-Gault).&#xD;
&#xD;
         12. Fertil men must be using adequate contraceptive measures throughout the study period&#xD;
             if their partner are women of childbearing potential.&#xD;
&#xD;
         13. If of childbearing potential, women must use effective contraceptive method (Pearl&#xD;
             Index &lt; 1; e.g. oral contraceptive (pill), hormone spiral, hormone implant,&#xD;
             transdermal patch, a combination of two barrier methods (condom and diaphragm),&#xD;
             sterilisation, sexual abstinence) for the study duration and for at least 6 months&#xD;
             after last avelumab treatment administration if the risk of conception exists.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of malignant disease (with the exception of non-melanoma skin tumours and/or&#xD;
             in situ cervical cancer) in the preceding five years.&#xD;
&#xD;
          2. Brain metastases.&#xD;
&#xD;
          3. Autoimmune disorders. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or&#xD;
             hyperthyroid diseases not requiring immunosuppressive treatment are eligible.&#xD;
&#xD;
          4. Allergic disorders.&#xD;
&#xD;
          5. Cyclophosphamide treatment contraindications:&#xD;
&#xD;
               1. Cystitis.&#xD;
&#xD;
               2. Urinary Obstruction.&#xD;
&#xD;
               3. Inadequate bone marrow function: WBC &lt;2900 mm3 and/or HCT &lt;30% and/or platelets&#xD;
                  count &lt;90000 mm3.&#xD;
&#xD;
               4. Active infections.&#xD;
&#xD;
               5. Pregnancy or breast feeding.&#xD;
&#xD;
          6. Prior treatment with inhibitors of the PD-L1 - PD - 1 axis or inhibitors of CTLA-4&#xD;
             (immune check point inhibitors)&#xD;
&#xD;
          7. Previous HBV or HCV infections.&#xD;
&#xD;
          8. Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal,&#xD;
             inhaled, topical steroids, or local steroid injection (e.g., intra-articular&#xD;
             injection); b. systemic corticosteroids at physiologic doses 10 mg/day of prednisone&#xD;
             or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT&#xD;
             scan premedication).&#xD;
&#xD;
          9. Any active infection requiring specific treatment (Antibiotics, antimicotic,&#xD;
             antiviral).&#xD;
&#xD;
         10. Radiotherapy within 6 weeks before enrolment&#xD;
&#xD;
         11. Other non-malignant uncontrolled systemic diseases or social conditions that would&#xD;
             preclude trial entry in the opinion of the investigator.&#xD;
&#xD;
         12. Prior organ transplantation including allogenic stem-cell transplantation.&#xD;
&#xD;
         13. Vaccination within 4 weeks of the first dose of avelumab and while on trials is&#xD;
             prohibited except for administration of inactivated vaccines.&#xD;
&#xD;
         14. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade &gt; 1); however,&#xD;
             alopecia, sensory neuropathy Grade 2, or other Grade 2 not constituting a safety risk&#xD;
             based on investigator's judgment are acceptable.&#xD;
&#xD;
         15. Other severe acute or chronic medical conditions including colitis, inflammatory bowel&#xD;
             disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent&#xD;
             (within the past year) or active suicidal ideation or behaviour; or laboratory&#xD;
             abnormalities that may increase the risk associated with study participation or study&#xD;
             treatment administration or may interfere with the interpretation of study results&#xD;
             and, in the judgment of the investigator, would make the patient inappropriate for&#xD;
             entry into this study.&#xD;
&#xD;
         16. Avelumab treatment contraindications:&#xD;
&#xD;
               1. Hypersensitivity to the active ingredient or to any excipient.&#xD;
&#xD;
               2. Inadequate bone marrow function: WBC &lt;2900 mm3 and/or HCT &lt;30% and/or platelets&#xD;
                  count &lt;90000 mm3.&#xD;
&#xD;
               3. Uncontrolled serous effusions (pleural, pericardic or peritoneal)&#xD;
&#xD;
               4. Blood Pressure &lt;60 mmHg.&#xD;
&#xD;
               5. Pregnancy or breast feeding.&#xD;
&#xD;
               6. Active infections. Known history of testing positive for HIV or known acquired&#xD;
                  immunodeficiency syndrome.&#xD;
&#xD;
               7. Brain metastases.&#xD;
&#xD;
               8. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular&#xD;
                  accident/stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6&#xD;
                  months prior to enrollment), unstable angina, congestive heart failure ( New York&#xD;
                  Heart Association Classification Class II), or serious cardiac arrhythmia&#xD;
                  requiring medication.&#xD;
&#xD;
         17. Participation to other concomitant experimental study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARCO C MERLANO, DR</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO S CROCE E CARLE DI CUNEO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MARCO C MERLANO, DR</last_name>
    <phone>+390171616739</phone>
    <phone_ext>6739</phone_ext>
    <email>MCMERLANO@GMAIL.COM</email>
  </overall_contact>
  <location>
    <facility>
      <name>AO Santa Croce e Carle di Cuneo</name>
      <address>
        <city>Cuneo</city>
        <state>Italia/cuneo</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MARCO C MERLANO, DR</last_name>
      <phone>+390171616739</phone>
      <phone_ext>6739</phone_ext>
      <email>MCMERLANO@GMAIL.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce E Carle Di Cuneo - Cuneo (Cn) Oncologia Medica</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Merlano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Merlano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331. Review.</citation>
    <PMID>18173375</PMID>
  </reference>
  <reference>
    <citation>Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26. Review.</citation>
    <PMID>23625198</PMID>
  </reference>
  <reference>
    <citation>Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009 Dec 21;206(13):3015-29. doi: 10.1084/jem.20090847. Epub 2009 Dec 14.</citation>
    <PMID>20008522</PMID>
  </reference>
  <reference>
    <citation>Li X, Kostareli E, Suffner J, Garbi N, Hämmerling GJ. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol. 2010 Dec;40(12):3325-35. doi: 10.1002/eji.201041093.</citation>
    <PMID>21072887</PMID>
  </reference>
  <reference>
    <citation>Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007 May;56(5):641-8. Epub 2006 Sep 8.</citation>
    <PMID>16960692</PMID>
  </reference>
  <reference>
    <citation>Haikerwal SJ, Hagekyriakou J, MacManus M, Martin OA, Haynes NM. Building immunity to cancer with radiation therapy. Cancer Lett. 2015 Nov 28;368(2):198-208. doi: 10.1016/j.canlet.2015.01.009. Epub 2015 Jan 12. Review.</citation>
    <PMID>25592036</PMID>
  </reference>
  <reference>
    <citation>Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015 May 28;4(11):e1046028. eCollection 2015 Nov.</citation>
    <PMID>26451318</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Avelumab</keyword>
  <keyword>Head and neck cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03844763/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

